Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612621 | 0.78 | NCF1 (0.37) | NCF1P2RX4ALDH1A1KDM4EPOLB | |
| SCHEMBL1490713 | 0.78 | KDM4E (0.43) | P2RX4ALDH1A1KDM4ESSTR4 | |
| SCHEMBL1473973 | 0.78 | — | — | |
| SCHEMBL16109103 | 0.78 | ALDH1A1 (0.34) | ALDH1A1POLB | |
| SCHEMBL7431480 | 0.78 | SMN1; SMN2 (0.48) | ALDH1A1KDM4E | |
| SCHEMBL27172377 | 0.76 | EPHX2 (0.59) | — | |
| SCHEMBL15808570 | 0.75 | KDM4E (0.44) | P2RX4ALDH1A1KDM4EPOLBSSTR4 | |
| SCHEMBL2257067 | 0.74 | — | — | |
| SCHEMBL1475935 | 0.74 | — | — | |
| SCHEMBL3894301 | 0.74 | EPHX1 (0.40) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160775-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | SAINT LOUIS UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| EP-0282133-B1 | 1-ALKYL SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-28 | — | — | EP | disclosed |
| EP-0282133-A2 | 1-alkyl substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296532-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | BACE2, DNPEP, ACE | PKM 2319/4885NCF1 4169/4885P2RX4 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.